$GRTX
Galera Therapeutics, Inc.

2024 Q3 Form 10-Q Financial Statement

#000095017024096654 Filed on August 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.779M
YoY Change -69.94%
% of Gross Profit
Research & Development $305.0K $1.430M
YoY Change -94.99% -81.09%
% of Gross Profit
Depreciation & Amortization $6.000K
YoY Change -50.0%
% of Gross Profit
Operating Expenses $305.0K $1.430M
YoY Change -94.99% -81.09%
Operating Profit -$5.908M -$4.209M
YoY Change -55.9% -74.96%
Interest Expense $0.00 $0.00
YoY Change -100.0% -100.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$5.784M -$4.064M
YoY Change -61.62% -80.38%
Income Tax $200.0K
% Of Pretax Income
Net Earnings -$5.581M -$4.064M
YoY Change -62.97% -80.38%
Net Earnings / Revenue
Basic Earnings Per Share -$0.10 -$0.07
Diluted Earnings Per Share -$0.10 -$0.07
COMMON SHARES
Basic Shares Outstanding 54.39M 54.39M
Diluted Shares Outstanding 54.39M 54.39M

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $10.75M
YoY Change -72.26%
Cash & Equivalents $8.455M $10.75M
Short-Term Investments
Other Short-Term Assets $1.213M
YoY Change -62.65%
Inventory
Prepaid Expenses $0.00 $0.00
Receivables
Other Receivables
Total Short-Term Assets $8.899M $11.96M
YoY Change -71.52% -71.52%
LONG-TERM ASSETS
Property, Plant & Equipment $0.00 $56.00K
YoY Change -100.0% -73.33%
Goodwill $0.00 $881.0K
YoY Change -100.0% 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.000K $90.00K
YoY Change -99.9% -94.51%
Total Long-Term Assets $2.000K $4.421M
YoY Change -99.97% -29.52%
TOTAL ASSETS
Total Short-Term Assets $8.899M $11.96M
Total Long-Term Assets $2.000K $4.421M
Total Assets $8.901M $16.38M
YoY Change -76.44% -66.06%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $296.0K $812.0K
YoY Change -92.03% -85.28%
Accrued Expenses $618.0K $1.157M
YoY Change -92.96% -85.5%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $914.0K $2.126M
YoY Change -92.76% -84.39%
LONG-TERM LIABILITIES
Long-Term Debt $151.0M
YoY Change 1.88%
Other Long-Term Liabilities $1.037M
YoY Change -13.08%
Total Long-Term Liabilities $152.1M
YoY Change 1.76%
TOTAL LIABILITIES
Total Short-Term Liabilities $914.0K $2.126M
Total Long-Term Liabilities $152.1M
Total Liabilities $152.0M $154.4M
YoY Change -7.53% -5.43%
SHAREHOLDERS EQUITY
Retained Earnings -$451.4M -$445.9M
YoY Change 4.54% 7.01%
Common Stock $308.4M $307.8M
YoY Change 1.02% 2.01%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$143.1M -$138.0M
YoY Change
Total Liabilities & Shareholders Equity $8.901M $16.38M
YoY Change -76.44% -66.06%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$5.581M -$4.064M
YoY Change -62.97% -80.38%
Depreciation, Depletion And Amortization $6.000K
YoY Change -50.0%
Cash From Operating Activities -$2.717M
YoY Change -74.72%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change -100.0%
Cash From Investing Activities $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -2.717M
Cash From Investing Activities 0.000
Cash From Financing Activities 0.000
Net Change In Cash -2.717M
YoY Change 96.17%
FREE CASH FLOW
Cash From Operating Activities -$2.717M
Capital Expenditures $0.00
Free Cash Flow -$2.717M
YoY Change -74.83%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001563577
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39114
dei Entity Registrant Name
EntityRegistrantName
Galera Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-1454898
dei Entity Address Address Line1
EntityAddressAddressLine1
45 Liberty Blvd, Suite 230
dei Entity Address City Or Town
EntityAddressCityOrTown
Malvern
dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19355
dei City Area Code
CityAreaCode
610
dei Local Phone Number
LocalPhoneNumber
725-1500
dei Security12b Title
Security12bTitle
Common Stock,$0.001 par value per share
dei Trading Symbol
TradingSymbol
GRTX
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
54392170
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10749000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18257000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1213000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3372000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
11962000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
21629000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
56000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
71000
CY2024Q2 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
2258000
CY2023Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
2258000
CY2024Q2 us-gaap Goodwill
Goodwill
881000
CY2023Q4 us-gaap Goodwill
Goodwill
881000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1136000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1212000
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
90000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
90000
CY2024Q2 us-gaap Assets
Assets
16383000
CY2023Q4 us-gaap Assets
Assets
26141000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
812000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1375000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1157000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3449000
CY2024Q2 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
157000
CY2023Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
133000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
2126000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4957000
CY2024Q2 us-gaap Royalty Guarantees Commitments Amount
RoyaltyGuaranteesCommitmentsAmount
151049000
CY2023Q4 us-gaap Royalty Guarantees Commitments Amount
RoyaltyGuaranteesCommitmentsAmount
151049000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1037000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1117000
CY2024Q2 us-gaap Deferred Tax Liabilities Derivatives
DeferredTaxLiabilitiesDerivatives
203000
CY2023Q4 us-gaap Deferred Tax Liabilities Derivatives
DeferredTaxLiabilitiesDerivatives
203000
CY2024Q2 us-gaap Liabilities
Liabilities
154415000
CY2023Q4 us-gaap Liabilities
Liabilities
157326000
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
54392170
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
54392170
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
54392170
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
54392170
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
54000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
54000
CY2024Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
307765000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
306167000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-445851000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-437406000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-138032000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-131185000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
16383000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
26141000
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1430000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7561000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2918000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14833000
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2779000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9246000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5868000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15855000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4209000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-16807000
us-gaap Operating Income Loss
OperatingIncomeLoss
-8786000
us-gaap Operating Income Loss
OperatingIncomeLoss
-30688000
CY2024Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
149000
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
494000
us-gaap Investment Income Interest
InvestmentIncomeInterest
345000
us-gaap Investment Income Interest
InvestmentIncomeInterest
889000
CY2024Q2 us-gaap Interest Expense
InterestExpense
0
CY2023Q2 us-gaap Interest Expense
InterestExpense
4399000
us-gaap Interest Expense
InterestExpense
0
us-gaap Interest Expense
InterestExpense
8622000
CY2024Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-4000
CY2023Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-0
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-4000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-1000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-4064000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-20712000
us-gaap Net Income Loss
NetIncomeLoss
-8445000
us-gaap Net Income Loss
NetIncomeLoss
-38422000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.07
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.48
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.48
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.16
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.16
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.98
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.98
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54392170
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54392170
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42916962
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42916962
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54392170
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54392170
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39077876
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
39077876
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-4064000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-20712000
us-gaap Net Income Loss
NetIncomeLoss
-8445000
us-gaap Net Income Loss
NetIncomeLoss
-38422000
CY2024Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-11000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
27000
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4064000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-20723000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8445000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-38395000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-131185000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
875000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-4381000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-134691000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
723000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-4064000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-138032000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-109181000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1458000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
184000
grtx Common Stock Issuance Costs
CommonStockIssuanceCosts
2403000
CY2023Q1 grtx Sale Of Shares Under Open Market Sale Agrrement
SaleOfSharesUnderOpenMarketSaleAgrrement
-27598000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
38000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-17710000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-97613000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1525000
CY2023Q2 grtx Stock Issued During Period Value Common Stock Warrants Exercised1
StockIssuedDuringPeriodValueCommonStockWarrantsExercised1
1812000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-11000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-20712000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-114999000
us-gaap Profit Loss
ProfitLoss
-8445000
us-gaap Profit Loss
ProfitLoss
-38422000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
15000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
32000
us-gaap Paid In Kind Interest
PaidInKindInterest
0
us-gaap Paid In Kind Interest
PaidInKindInterest
8622000
us-gaap Share Based Compensation
ShareBasedCompensation
1598000
us-gaap Share Based Compensation
ShareBasedCompensation
2983000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
72000
grtx Refundable Pdufa Fees
RefundablePdufaFees
0
grtx Refundable Pdufa Fees
RefundablePdufaFees
3242000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2159000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-768000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-76000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-309000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-563000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1935000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2292000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1777000
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
56000
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
32000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7508000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22412000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
0
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
18596000
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
0
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
31500000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
50000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
12854000
grtx Proceeds From Sale Of Common Stock And Common Stock Warrants In Registered Direct Offering
ProceedsFromSaleOfCommonStockAndCommonStockWarrantsInRegisteredDirectOffering
0
grtx Proceeds From Sale Of Common Stock And Common Stock Warrants In Registered Direct Offering
ProceedsFromSaleOfCommonStockAndCommonStockWarrantsInRegisteredDirectOffering
27598000
grtx Proceeds From The Exercise Of Common Stock Warrants
ProceedsFromTheExerciseOfCommonStockWarrants
0
grtx Proceeds From The Exercise Of Common Stock Warrants
ProceedsFromTheExerciseOfCommonStockWarrants
1812000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
184000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
29594000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7508000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
20036000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18257000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4316000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10749000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24352000
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
0
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
1310000
grtx Sale Of Property And Equipment In Exchange For Prepaid Future Services
SaleOfPropertyAndEquipmentInExchangeForPrepaidFutureServices
0
grtx Sale Of Property And Equipment In Exchange For Prepaid Future Services
SaleOfPropertyAndEquipmentInExchangeForPrepaidFutureServices
319000
CY2023Q3 grtx Number Of Reduction In Companys Current Workforce Employees
NumberOfReductionInCompanysCurrentWorkforceEmployees
22
CY2023Q3 grtx Workforce Reduction Rate
WorkforceReductionRate
0.70
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-445900000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of unaudited interim consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the unaudited interim consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the unaudited interim consolidated financial statements in the period they are determined to be necessary. Significant areas that require management’s estimates include share-based compensation assumptions, royalty purchase liability assumptions and accrued research and development expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2023 us-gaap Restructuring Charges
RestructuringCharges
2300000
CY2024Q2 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
0
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19380222
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
21724527
us-gaap Fair Value Liabilities Measured On Recurring Basis Debt Instrument Valuation Techniques Change In Technique Quantification Of Effect
FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect
0
CY2024Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
0
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1450000
CY2024Q2 us-gaap Prepaid Insurance
PrepaidInsurance
535000
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1302000
CY2024Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
678000
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
620000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1213000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3372000
CY2024Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
530000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
530000
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
474000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
459000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
56000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
71000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
15000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
32000
CY2024Q2 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
825000
CY2023Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
121000
us-gaap Restructuring Costs
RestructuringCosts
0
CY2023 us-gaap Restructuring Costs
RestructuringCosts
443000
CY2024Q2 grtx Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
211000
CY2023Q4 grtx Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
2672000
CY2024Q2 grtx Accrued Professional Fees And Other Expenses Current
AccruedProfessionalFeesAndOtherExpensesCurrent
121000
CY2023Q4 grtx Accrued Professional Fees And Other Expenses Current
AccruedProfessionalFeesAndOtherExpensesCurrent
213000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1157000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3449000
CY2024Q2 us-gaap Debt Instrument Interest Rate Effective Percentage
DebtInstrumentInterestRateEffectivePercentage
0
CY2024Q2 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P6Y
CY2024Q2 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
4700000
CY2024Q2 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P6Y3M18D
CY2024Q2 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.054
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1136000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1212000
CY2024Q2 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
157000
CY2023Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
133000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1037000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1117000
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1194000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1250000
CY2024Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
54000
CY2023Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
36000
us-gaap Operating Lease Expense
OperatingLeaseExpense
108000
us-gaap Operating Lease Expense
OperatingLeaseExpense
84000
CY2024Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
54000
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
36000
us-gaap Operating Lease Cost
OperatingLeaseCost
108000
us-gaap Operating Lease Cost
OperatingLeaseCost
84000
us-gaap Operating Lease Payments
OperatingLeasePayments
88000
us-gaap Operating Lease Payments
OperatingLeasePayments
44000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1310000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
107000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
217000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
220000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
224000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
633000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1401000
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
207000
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1194000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Purchased For Award
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
14320000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Purchased For Award
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
14320000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Per Share Weighted Average Price Of Shares Purchased
ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased
2.095
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
27600000
CY2023Q1 us-gaap Warrant Exercise Price Increase
WarrantExercisePriceIncrease
1.97
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P5Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Purchased For Award
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
13300000
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
723000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1525000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1598000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2983000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5739488
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.85
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y7M6D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
209927
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
5.73
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5529561
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.85
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y2M12D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4315112
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
6.69
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y7M6D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
5529561
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
5.85
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y2M12D
CY2024Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
2600000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y8M12D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.66
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y2M12D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.953
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0405
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Restructuring Charges
RestructuringCharges
2300000
CY2023Q4 us-gaap Restructuring Reserve
RestructuringReserve
443000
us-gaap Restructuring Reserve Accrual Adjustment1
RestructuringReserveAccrualAdjustment1
0
us-gaap Payments For Restructuring
PaymentsForRestructuring
443000
CY2024Q2 us-gaap Restructuring Reserve
RestructuringReserve
0
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-096654-index-headers.html Edgar Link pending
0000950170-24-096654-index.html Edgar Link pending
0000950170-24-096654.txt Edgar Link pending
0000950170-24-096654-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
grtx-20240630.htm Edgar Link pending
grtx-20240630.xsd Edgar Link pending
grtx-ex10_1.htm Edgar Link pending
grtx-ex31_1.htm Edgar Link pending
grtx-ex31_2.htm Edgar Link pending
grtx-ex32_1.htm Edgar Link pending
grtx-ex32_2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
grtx-20240630_htm.xml Edgar Link completed
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable